Abstract
Objective Divergent findings in structural brain alterations in psychoses suggest that often-observed regions may exist within a network of susceptible regions. We built structural covariance networks (SCN) of volumes, cortical thickness, and surface area using the Human Connectome Project atlas-based parcellation of 358 regions on structural MRI data from 79 first-episode antipsychotic-naive psychosis patients (FEAP) and 68 controls.
Methods Using graph theoretic methods, we obtained representative graph metrics of integration, segregation, resilience, centrality, importance, community structure, and hub distribution for all 3-morphometric features. We compared networks for resilience by simulated removal (“attacks”) of nodes and hubs, and simulated replacement of correlations among nodes in FEAP with that of controls using DeltaCon metric.
Results Volume and thickness SCNs of FEAP showed differences in many graph metrics in opposite directions compared to controls but not surface area SCN. Network resilience did not show differences in the replacement simulation and hub “attacks, but betweenness centrality-based node “attacks” showed FEAP network disintegrating with relatively fewer node removals with preserved global efficiency compared to controls. In FEAP, communities consisted of regions from different lobes and hubs were more distributed than in controls.
Conclusions Our findings suggest decreased heterogeneity and less differentiated community structure of FEAP network that may not be attributed to illness chronicity and medications. Contribution of cortical thickness but not surface area suggests that disease/developmental processes may preferentially affect cortical thickness. Near-similar resilience of FEAP and control networks may shield controls from developing illness but may prevent fuller long-term recovery in FEAP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIMH R0MH1112584 and R01MH115026 (Konasale Prasad, MD); P50 MH045156, Behavioral Neuroscience and Schizophrenia (David Lewis, MD); and NIH/NCRR/GCRC M01 RR00056 (Arthur Levine, MD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Pittsburgh Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title is modified to fit the findings better. Abstract and text has been modified along with new figures and supplemental information.
Data Availability
All data produced in the present work are contained in the manuscript.
